Video Archives

The Importance of Diagnosing and Treating Oligometastatic Prostate Cancer and ADT Usage

Posted by Marc B. Garnick, MD | Jun 2024

Dr. Marc Garnick explores the diagnosis and treatment of oligometastatic prostate cancer with the strategic use of androgen deprivation therapy (ADT). Advanced imaging techniques are essential for identifying oligometastatic disease, such as PET scans and advanced MRI. These technologies enhance the precision of detecting small metastatic lesions, facilitating timely and appropriate treatment decisions. By reducing androgen levels that fuel prostate cancer growth, the strategic use of ADT not only helps in controlling the primary tumor but also in managing metastatic lesions, thereby extending the therapeutic window and improving overall survival rates.
Dr. Garnick also addresses the timing and duration of ADT in the context of oligometastatic prostate cancer. He highlights individualized treatment plans based on patient-specific factors, including the extent of disease, patient health status, and response to initial therapies. This personalized approach ensures that patients receive the most effective treatment while minimizing potential side effects associated with prolonged ADT usage.

International, Multi-Disciplinary Consensus on Treatment of Advanced Prostate Cancer

Posted by Silke Gillessen, MD | Jun 2024

Silke Gillessen, MD analyzes the international, multi-disciplinary consensus on the treatment of advanced prostate cancer, emphasizing the collaborative efforts of experts from various medical fields. She highlights the critical importance of integrating diverse perspectives to develop effective treatment protocols.

The consensus process involves an extensive review of clinical data, expert opinions, and patient outcomes, ensuring that the recommendations are evidence-based and practical. Dr. Gillessen discusses key areas of agreement for treatment, including hormone therapy, chemotherapy, and novel targeted therapies.

Dr. Gillessen highlights the potential of new treatment modalities, such as PARP inhibitors and immunotherapies. Moreover, she advocates for treatment plans tailored to individual patient profiles, taking into account genetic, molecular, and clinical factors. This approach aims to enhance treatment efficacy and minimize adverse effects, aligning with the principles of precision oncology.

In-Office Procedures and the ‘Scope’ of Practice for APPs

Posted by Terran W. Sims, NP, MSN, ACNP-C, CNN, COCN-C | Jun 2024

Terran W. Sims, NP, MSN, ACNP-C, CNN, COCN-C, discusses how to prepare and incorporate advanced practice providers (APPs) like nurse practitioners and physician assistants in urologic procedures. Ms. Sims begins by listing office procedures APPs might encounter, focusing on cystoscopy, stent removal, and difficult catheter insertion. She continues by posing a guiding question for her discussion: what is the best fit for APPs in practice?

Ms. Sims then briefly reviews differences in the scope of practice for APPs across the U.S., noting important state licensure requirements and highlighting the increasing presence of APP participation in urologic procedures. She emphasizes the American Urological Association’s (AUA) and Society of Urologic Nurses and Associates’ (SUNA) support for APP involvement, and utilizes cystoscopy as an example by detailing data that show increased levels of patient satisfaction as APPs have performed greater numbers of cystoscopy procedures.

Ms. Sims concludes by addressing the primary obstacles to additional APP role expansion: the lack of training and lack of standard curriculum. She encourages urologists to overcome these obstacles and invest in APPs by providing training, instilling confidence, and maintaining mentorship. She reiterates the benefits of APP involvement, including increased cost-effectiveness, profit margins, and team productivity.

Radiation Therapy Planning Using Advanced Imaging – Pearls and Pitfalls

Posted by Sean P. Collins MD, PhD | Jun 2024

Dr. Sean P. Collins discusses radiation therapy planning for prostate cancer, emphasizing the role of advanced imaging technologies. He underscores how these technologies enhance the precision of targeting cancerous tissues while minimizing radiation exposure to surrounding healthy tissues.
Dr. Collins elaborates on various advanced imaging modalities, including multiparametric MRI and PET/CT scans. He believes that integrating these imaging techniques into the radiation therapy planning process can result in more precise dose distributions, leading to better tumor control and fewer adverse effects.
Despite the clear advantages, Dr. Collins also addresses the potential pitfalls associated with advanced imaging in radiation therapy planning. Variability in image quality, the potential for imaging artifacts, and the necessity for specialized expertise in interpreting complex imaging data are addressed, as well as ways to mitigate these challenges.

Optilume® BPH Catheter System: Optilume® BPH Product and Clinical Data Overview – Additional Thoughts

Posted by E. David Crawford, MD | Jun 2024

David Crawford, MD, continues the conversation of the evolution of BPH treatments and the Optilume® BPH Catheter System with Dean S. Elterman, MD, MSC, FRCSC, and Stephen Kaplan, MD. To watch the main video, click here.